Summit Therapeutics shares fell after the Food and Drug Administration rejected the company’s application for ivonescimab with chemotherapy in EGFR-mutated, non-small cell lung cancer. The agency said delaying tumor progression in a late-stage study did not by itself support a positive benefit-risk profile, Summit said Sunday.
The decision followed results from HARMONi, which compared ivonescimab plus chemotherapy with chemotherapy alone in patients whose disease had progressed after targeted therapy. Summit reported that the combination delayed disease progression or death by more than two months, but the primary trial analysis did not clearly show longer survival.
Ivonescimab Review Turns on Survival Evidence
An analysis conducted after the primary evaluation, including additional participants enrolled at trial sites outside Asia, found a survival benefit, according to the report. The FDA did not accept those later results as sufficient for the application.
Summit argued in its statement that ivonescimab faced a higher approval bar than other available medicines for EGFR-mutated lung cancer. The company said no other FDA-approved regimens in this particular treatment setting had demonstrated a survival benefit. Those statements reflect Summit’s position following the agency’s decision.
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Summit chairman and co-CEO Robert Duggan said in the statement. Duggan said the company pursued the regimen because it believed it could provide another option for patients in need.
The market reaction began before the FDA deadline. Summit shares declined by 6% on Friday ahead of the decision deadline, then fell another 15% on Monday. Akeso, which developed ivonescimab and licensed most rights to Summit in 2022, saw its Hong Kong-traded shares fall 22% on Monday.
HARMONi Findings Split Analyst Views
Analysts had disagreed about whether ivonescimab’s survival results would support approval. TD Cowen’s Tyler Van Buren argued the survival benefit detected later should be enough. Leerink Partners analyst Daina Graybosch had cited an FDA statement that the benefit needed to appear in the study’s primary analysis.
Van Buren called the decision disappointing in a Sunday client note, while saying it matched the high bar the FDA had previously communicated. Graybosch wrote that the verdict suggested survival findings in other China-only studies did not overcome the results from the global HARMONi trial.
Graybosch also wrote that Summit might not be able to rely on results from HARMONi-6, a China study, to support a filing in another lung cancer setting. That was her assessment of the potential effect of the FDA decision, not an announced regulatory determination.
The next major data event is expected by the end of the year. Summit and Akeso should report results from a study comparing ivonescimab and chemotherapy with Keytruda and chemotherapy in first-line lung cancer. Van Buren said the rejection should have limited read-through to that larger opportunity.
The FDA’s rejection concerns the specific HARMONi application and evidence submitted for this treatment setting. Further results from the separate first-line study are the next company-reported milestone described in the source. Readers can also follow other treatment research, including small cell lung cancer research, a separate account of a rare tumor drug approval, and reporting on a pancreatic cancer vaccine trial.
Read the BioPharma Dive report for the source account of the decision and analyst reactions.

